Search Results - "Nguyen, Huong (Marie)"

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms by Hinds, David A., Barnholt, Kimberly E., Mesa, Ruben A., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce Y., Nguyen, Huong (Marie), Zhang, Haiyu, Gojenola, Linda, Zehnder, James L., Gotlib, Jason

“…We conducted a genome-wide association study (GWAS) to identify novel predisposition alleles associated with Philadelphia chromosome-negative…”
Get full text

Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated with Intravenous Unfractionated Heparin by Price, Elizabeth A, Jin, Jing, Nguyen, Huong Marie, Krishnan, Gomathi, Bowen, Raffick, Zehnder, James L

“…BACKGROUND: Both the activated partial thromboplastin time (aPTT) and anti-Xa assay can be used to monitor unfractionated heparin (UFH). Following…”
Get full text

Is there a role for the use of IFN-α in primary myelofibrosis? by Nguyen, Huong Marie, Kiladjian, Jean-Jacques

“…A 62-year-old man with a history of diabetes and hypertension is referred to your hematology clinic for an incidental discovery of anemia. He does not have any…”
Get full text

Is there a role for the use of IFN-α in primary myelofibrosis? by Nguyen, Huong Marie, Kiladjian, Jean-Jacques

“…A 62-year-old man with a history of diabetes and hypertension is referred to your hematology clinic for an incidental discovery of anemia. He does not have any…”
Get full text

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis by Luker, Gary D, Nguyen, Huong Marie, Hoff, Benjamin A, Galbán, Craig J, Hernando, Diego, Chenevert, Thomas L, Talpaz, Moshe, Ross, Brian D

“…Myelofibrosis (MF) is a hematologic neoplasm arising as a primary disease or secondary to other myeloproliferative neoplasms (MPNs). Both primary and secondary…”
Get full text

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, Armstrong, Andrew J.

“…134 Background: Androgen receptor (AR) signaling is the principal driver of PC at all stages. CC-94676 (BMS-986365) is a heterobifunctional, first-in-class,…”
Get full text

Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001) by Paz-Ares, Luis G., Senan, Suresh, Planchard, David, Wang, Luhua, Cheong, Alicia, Nguyen, Marie Huong, Slepetis, Ruta, Vokes, Everett E.

“…Abstract only TPS8574 Background: cCRT improves survival vs RT alone and is a global standard of care in patients (pts) with stage III NSCLC, but survival…”
Get full text

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers by Kamal, Menghrajani, Boonstra, Philip S., Weber, Alissa A., Perkins, Cecelia, Gowin, Krisstina L., Nguyen, Huong (Marie), Mesa, Ruben, Gotlib, Jason R., Talpaz, Moshe

“…Background: JAK2 inhibitors have been shown to improve symptoms and produce durable reductions in splenomegaly in patients with myelofibrosis (MF), and…”
Get full text

FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience by Nguyen, Huong (Marie), Pham, Anh, Perkins, Cecelia, Linder, Andrea, Fechter, Lenn, Gotlib, Jason

“…Abstract 1747 The oral JAK 1/2 inhibitor ruxolitinib (RUX) was approved in November 2011 for patients (pts) with IPSS intermediate (INT) or high-risk…”
Get full text

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms by Stein, Brady L, Gotlib, Jason, Arcasoy, Murat, Nguyen, Marie Huong, Shah, Neil, Moliterno, Alison, Jamieson, Catriona, Pollyea, Daniel A, Scott, Bart, Wadleigh, Martha, Levine, Ross, Komrokji, Rami, Klisovic, Rebecca, Gundabolu, Krishna, Kropf, Patricia, Wetzler, Meir, Oh, Stephen T, Ribeiro, Raul, Paschal, Rita, Mohan, Sanjay, Podoltsev, Nikolai, Prchal, Josef, Talpaz, Moshe, Snyder, David, Verstovsek, Srdan, Mesa, Ruben A

“…The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and…”
Get more information

Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors by Menghrajani, Kamal, Boonstra, Philip, Weber, Alissa, Perkins, Cecelia, Gowin, Krisstina, Nguyen, Huong (Marie), Mesa, Ruben, Gotlib, Jason, Talpaz, Moshe

Get full text

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy by Meadows, Sarah A, Nguyen, Huong (Marie), Queva, Christophe, Lannutti, Brian J., Kashishian, Adam, Jun, Susie, Coutre, Steven E., Dansey, Roger, Gotlib, Jason

“…Myelofibrosis (MF) is characterized by activation of the JAK-STAT pathway, with the JAK2 V617F mutation found in 50-60% of patients. Although JAK inhibitors,…”
Get full text

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy by Ottmann, Oliver G., Alimena, Giuliana, DeAngelo, Daniel J., Goh, Yeow-Tee, Heinrich, Michael C., Hochhaus, Andreas, Hughes, Timothy P., Mahon, Francois-Xavier, Mauro, Michael J., Minami, Hironobu, Nguyen, Marie Huong, Rea, Delphine, Steegmann, Juan Luis, Chatterjee, Arkendu, Iyer, Varsha, Martinez, Noelia, Vanasse, Gary J., Dong-Wook, Kim

“…▪ Background: ABL001 is a potent, specific BCR-ABL inhibitor in development for the treatment of patients with chronic myelogenous leukemia (CML) and…”
Get full text

Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts by Barnholt, Kimberly E., Hinds, David A., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce A., Nguyen, Huong (Marie), Levine, Ross L., Mesa, Ruben A., Gotlib, Jason, Zehnder, James L.

“…Abstract 1737 The somatic JAK2 V617F (V617F) mutation is found in approximately 95% of polycythemia vera (PV) and 50–60% of essential thrombocythemia (ET) and…”
Get full text

A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms by Hinds, David A., Barnholt, Kimberly E., Zehnder, James L., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce A., Nguyen, Huong (Marie), Levine, Ross L., Mesa, Ruben A., Gotlib, Jason

“…Abstract 707 Myeloproliferative neoplasms (MPNs) are disorders that result in unregulated overproduction of one or more myeloid blood cell types by the bone…”
Get full text

Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients by Nguyen, Huong (Marie), Hinds, David A., Barnholt, Kimberly E., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce A., Levine, Ross L., Zehnder, James L., Gotlib, Jason, Mesa, Ruben A.

“…Abstract 1732 In addition to chronic myelogenous leukemia (CML), the classic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential…”
Get full text